Abstract: Disclosed is a method of diagnosing multiple sclerosis (MS), wherein a blood sample from a patient is incubated with a DNA-replication associated (REP) protein. The present invention relates to a DNA-replication-associated (Rep) protein for use in the diagnosis of multiple sclerosis (MS), wherein (a) an increased amount of Rep protein or fragments thereof in the sample as compared to an amount in a control sample; or an increased amount of anti-Rep protein antibodies with antigen in a sample from a subject as compared to an amount in a control sample correlates with a diagnosis of MS, wherein the Rep protein is MSBI1 Rep or MSBI2 Rep.

Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

Abstract: The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of inflammatory or autoimmune diseases or cancer.

Abstract: The invention provides methods of treating taupathies such as Alzheimer's disease with antibodies that bind to human tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

Abstract: In Provided herein are compositions and methods directed to treating, delaying progression of, or ameliorating symptoms related to disorders characterized with TGF-? activity (e.g., disorders characterized with aberrant cartilage formation and/or osteoclast resorption (e.g., ankylosing spondylitis)) (e.g., spinal cord injuries) (e.g., fibrotic scar formation following spinal cord injury) through inhibition of TGF-? activity (e.g., thereby hindering and/or inhibiting aberrant cartilage formation and/or osteoclast resorption within joints, muscles, tendons, ligaments, connective tissue, and/or bones experiencing or at risk of experiencing ankylosis) (e.g., thereby inhibiting fibrotic scar formation following spinal cord injury).

Abstract: Disclosed herein are anti-CCL21 antibodies useful in treating autoimmune diseases, treating or preventing allograft transplant rejection, and treating metastatic cancer or preventing cancer metastasis in a subject.

Abstract: The present disclosure relates to antibodies, for example monoclonal antibodies, and their use in clinical patient evaluation and therapy. The present disclosure further relates to a method for modulating the activity of human CXCL-1 protein (hereinafter, referred to as CXCL1). In an aspect, antibodies described herein are capable of being used as a medicament for the prevention and/or treatment of diseases involving CXCL1 function, for example, pathological angiogenesis and inflammatory diseases.

Abstract: Methods for treating or mitigating COVID-19, sepsis or hemophagocytic lymphohistiocystosis or cytokine storm-associated syndromes; and treating or preventing inflammatory cell death associated with an inflammatory condition or infection such as SARS-CoV-2, or inducing inflammatory cell death in the context of cancer are provided, which includes the modulation of TNF and/or IFN-? activity.

Abstract: The present disclosure generally relates to pharmaceutical compositions useful for the treatment of diseases and disorders. More particularly, the disclosure relates to immunotherapy comprising intranasal immunotherapy with neutralizing monoclonal antibodies (mAbs) against IL-12 p40 homodimer for the treatment of an Alzheimer's disease.

Abstract: The present invention relates to the treatment of inflammatory bowel disease (IBD) with anti-IL36R antibodies.

Abstract: The present invention relates to an affibody that binds to testosterone, and uses thereof. An affibody or a complex of affibody and osteopontin fragments, of the present invention, has superior effects on hair growth or hair loss prevention, and thus can be effectively used as a hair growth agent or a hair loss treatment agent.

Abstract: The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.

Abstract: The present invention provides a CD19-targeting humanized antibody, and a multispecific antibody, chimeric receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD19-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD19 expression.

Abstract: The present invention relates to the field of treatment of diseases. Specifically, the present invention relates to an anti-ROR1 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding same, and methods for preparing same. The anti-ROR1 antibody or the antigen-binding fragment thereof of the present invention has high specificity and high affinity for ROR1, and can effectively bind ROR1 and mediate killing of ROR1 expression cells. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in preparation of a drug which is used for prevention and/or treatment of tumors.

Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.

Abstract: The present invention generally relates to antibodies that bind to CD3 and PLAP, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Abstract: Provided are anti-CD8 antibodies that bind human CD8 and do not stimulate or inhibit the activation of CD8+ T cells. Also provided are nucleic acids encoding such anti-CD8 antibodies, vectors comprising such nucleic acids, host cells comprising same, and methods of making such anti-CD8 antibodies. Also provided are anti-CD8 antibodies conjugated to a detectable label. Provided are methods of using such anti-CD8 antibodies to detect CD8+ T cells in a subject, monitor disease progress in a subject having cancer, and monitor treatment progress in a subject having cancer.

Abstract: Provided herein are methods of treating cancer using LSD1 inhibitors in combination with immunotherapy.

Abstract: The present invention discloses an antibody that specifically binds to human CTLA4, comprising three complementarily-determining regions; the three complementarity-determining regions are respectively: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3. Also disclosed are medicaments and kits comprising the antibodies described above. The antibodies of the present invention exhibit, but are not limited to, the following properties: (1) high affinity and specificity with human CTLA4; (2) able to block the interaction of CTLA4 with CD86 or CD80; (3) able to specifically bind to CTLA4 overexpressing cells; (4) enhancing activation of PBMC and/or T cells; (5) inhibiting tumor growth.

Abstract: The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof.

Abstract: The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

Abstract: Dosage regimens of anti-Blood Dendritic Cell Antigen 2 antibodies are provided for use in the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus.

Abstract: The present invention describes compositions and methods for targeting complement inhibition to sites of p-selectin expression, and compositions for inhibiting p-selectin and complement.

Abstract: The present invention relates to a combination comprising a Treg depletor and an LTBR agonist. Such a combination is particularly useful for use in the treatment of a cancer.

Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.

Abstract: Provided in the present invention are a BCMA-targeting single-domain antibody and an encoding nucleotide sequence thereof. Also provided in the present invention are a multispecific antibody, a chimeric antigen receptor, and an antibody conjugate containing the BCMA single domain antibody, and a pharmaceutical composition and kit containing said antibodies, chimeric antigen receptor and antibody conjugate, and the use thereof in the diagnosis/treatment/prevention of diseases associated with BCMA expression.

Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

Abstract: An anti-CD73 antibody and the use thereof. The heavy chain variable region of the antibody comprises HCDR1-HCDR3 having amino acid sequences as shown in SEQ ID NOs: 15-17; and the light chain variable region of the antibody comprises LCDR1-LCDR3 having amino acid sequences as shown in SEQ ID NOs: 18-20.

Abstract: An anti-SIRP? antibody or an antigen-binding fragment thereof, and use thereof are provided. The anti-human SIRP? monoclonal antibody is obtained by means of immunizing mice, and a chimeric antibody and a humanized antibody are further obtained. The provided anti-SIRP? antibody or antigen-binding fragment thereof can bind to the human SIRP? protein, block the CD47-SIRP? signaling pathway, and have immune regulation effects such as enhancing phagocytosis. Further provided are a pharmaceutical composition and a nucleic acid molecule, and the use of the anti-SIRP? antibody or the antigen-binding fragment thereof in the preparation of a drug for inhibiting or treating diseases.

Abstract: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.

Abstract: The present invention provides monoclonal antibodies that recognize poliovirus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.

Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRP?Fc is enhanced in the presence of daratumumab. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.

Abstract: The invention relates to engineered nolyneptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variantg cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.

Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.

Abstract: The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an Fc?R that activates a cellular effector (“Fc?RActivating,” such as Fc?RIIA or Fc?RIIIA) and an Fc?R that inhibits a cellular effector (“Fc?Inhibiting,” such as Fc?RIIA) with an altered Ratio of Affinities relative to the respective binding affinities of such Fc?R for the Fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g.

Abstract: An antibody specific to GPC3 (Glypican 3) and uses thereof, and more particularly, to an antibody that specifically binds to GPC3, a chimeric antigen receptor comprising the antibody, a CAR-T cell expressing the chimeric antigen receptor, and a pharmaceutical composition for preventing or treating diseases mediated by cells expressing GPC3 comprising the same are provided. Antibodies that more specifically bound to GPC3 were screened to establish six novel antibodies (10E9, 8B2, 7C6, 7B9, 5E11, 1A8), and it was confirmed that the novel antibodies specifically bound to GPC3 antigen. Since it was confirmed that GPC3-CAR-T cells prepared in the present invention effectively recognized the GPC3 antigen, induced activation of the CAR-T cells, and effectively killed cells expressing GPC3, GPC3-specific antibody of the present invention, the chimeric antigen receptor prepared using the same and CAR-T cell(s) can be applied to the prevention or treatment of cancers or tumors expressing GPC3.

Abstract: The present invention provides antibodies that target glioblastoma stem-like cells and methods and kits for their use.

Abstract: The present invention relates to methods for the in vitro diagnosis of ovarian cancer, and to compositions and methods for the prevention or the treatment of ovarian cancer. Disclosed are compositions that include an antibody binding to progastrin and disclosed are methods that include the use of an antibody binding to progastrin.

Abstract: The present application provides a recombinant binding protein that specifically binds to HDAC6 and blocks the ubiquitin-engaging zinc finger domain of HDAC6.

Abstract: Multi-specific binding proteins that bind CD123, the NKG2D receptor, and CD16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

Abstract: The present invention relates to novel anti-IgG nanobodies, particularly nanobodies directed against rabbit or mouse IgG. Further, the invention relates to the use of said nanobodies and methods for producing them.

Abstract: Provided herein are anti-idiotype antibodies that specifically recognize anti-CD19 antibody moieties, in particular, anti-CD19 antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of anti-idiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-CD19 CART cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.

Abstract: Immunotherapeutic proteins comprising at least one heavy chain polypeptide derived from an IgG2 antibody are disclosed, wherein the heavy chain polypeptide comprises at least constant heavy domains 2 and 3 (CH2 and CH3) and the lower hinge, and the sequence of the lower hinge comprises a mutation enabling the immunotherapeutic protein to bind to and/or activate Fc?RIIb. The immunotherapeutic protein is suitable for use in methods of treating diseases or conditions wherein, for example, the activation of Fc?RIIb (ie for recruitment of the inhibitory functions of Fc?RIIb) is beneficial, such as allergic diseases.

Abstract: Provided herein are compositions and methods for detection of N6-methyladenosine (m6A) in ribonucleic acid (RNA). The provided compositions include fusion proteins that can be used to edit RNA and detect m6A residues. Also provided are nucleic acids, vectors, constructs, host cells, and transgenic animals that encode or express such fusions proteins.

Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.

Abstract: the present invention provides a method for producing a protein having a supramolecular structure in which a bioactive substance is encapsulated, comprising: (I) bringing a subunit of a protein, which forms a supramolecular structure, a bioactive substance, and a solution for forming the protein having the supramolecular structure from the subunit into contact with one another in a flow micro mixer.